News | Radiation Therapy | July 30, 2018

MIM Software Inc. Collaborating With Radialogica to Provide Monte Carlo Dose Calculation

Partnership will combine MIM Software’s imaging and registration tools with Radialogica’s dose calculation capabilities

MIM Software Inc. Collaborating With Radialogica to Provide Monte Carlo Dose Calculation

July 30, 2018 — MIM Software Inc. announced its intention to collaborate with Radialogica to provide an integrated, advanced Monte Carlo dose calculation algorithm for adaptive radiation therapy assessment and quality assurance. MIM Software is currently demonstrating its latest solutions at the 2018 American Association of Physicists in Medicine (AAPM) annual meeting, July 29-Aug. 2 in Nashville.

Monte Carlo simulation is considered the gold standard in dose calculation. MIM Software CEO Andrew Nelson said the partnership will allow the companies to combine automation and dose calculation on a vendor-neutral platform.  

Combined with MIM Software's imaging and registration tools, the addition of an advanced Monte Carlo dose calculation algorithm will provide a leap forward in automating adaptive assessment during therapy while providing 3-D dose verification using independently verified beam models.

Through a previous partnership with Scientific RT, Radialogica offers the SciMoCa dose calculation algorithm.

For more information: www.mimsoftware.com, www.radialogica.com

Related Content

SmartCurve technology, a revolutionary breast imaging technology designed specifically for the curvature of the female breast to provide every woman with a more comfortable and accurate mammogram.
News | Mammography | September 14, 2018
Solis Mammography declared September Breast Wellness Month a
At RSNA 2018, radiology professionals will discover intelligent radiography powered by MUSICA, at Agfa's booth.

At RSNA 2018, radiology professionals will discover intelligent radiography powered by MUSICA, at Agfa's booth.

News | Digital Radiography (DR) | September 13, 2018
At RSNA 2018, radiology professionals will discover intelligent
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Veye Chest version 2
News | Lung Cancer | September 11, 2018
Aidence, an Amsterdam-based medical AI company, announced that Veye Chest version 2, a class IIa medical device, has
Sponsored Content | Whitepapers | Radiation Dose Management | September 10, 2018
It’s crucial for medical professionals to understand the radiation risk/ benefit balance of diagnostic imaging system
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
Overlay Init